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Cancer cells reprogram their metabolism to support a high proliferative rate. A new study shows that, upon
serine starvation, the tumor suppressor p53 activates p21 to shift metabolic flux from purine biosynthesis to
glutathione production, which enhances cellular proliferation and viability by combating ROS (Maddocks
et al., 2013).Cancer cells have designated hallmarks
differentiating them from nonneoplastic
cells: genomic instability, resistance to
cell death, uncontrolled proliferation,
and metabolic reprogramming, to
name a few (Hanahan and Weinberg,
2011). The latter has been gaining
increased attention. Cancer cells can
reprogram their metabolism by shifting
from oxidative phosphorylation to aerobic
glycolysis, which defines the Warburg
effect (Ward and Thompson, 2012).
Although aerobic glycolysis produces
far less ATP, an increase in macromole-
cule production along with an avoid-
ance of heightened ROS accumulation
from oxidative phosphorylation have
been postulated for this metabolic re-
programming (Vander Heiden et al.,
2009). Recent advances have shown
that several features of altered metabo-
lism can be dictated by specific onco-
genes or tumor suppressors (Ward
and Thompson, 2012). Classically known
for inhibiting malignant transformationby regulating DNA repair, cell-cycle
arrest, and apoptosis, the tumor
suppressor p53 also upregulates meta-
bolic targets to inhibit tumorigenesis (Li
et al., 2012). Further, recent evidence
suggests that p53 may also regulate
glycolysis and oxidative phosphorylation
in a cell- and context-specific manner
(Gottlieb and Vousden, 2010). In an
elegant study conducted by Karen Vous-
den’s group, Maddocks et al. demon-
strate that serine starvation activates
p53 to reprogram metabolism and
increase cancer cell survival (Maddocks
et al., 2013).
Reprogramming metabolic flux makes
cancer cells increasingly dependent on
specific metabolites; de novo serine
synthesis has been recently shown to be
crucial for cancer cell proliferation and
survival (Chaneton et al., 2012; Locasale
et al., 2011). Under serine starvation
conditions, Maddocks et al. initially ob-
served a decrease in cell proliferation
and survival that was more pronouncedin p53-deficient colon cancer cells com-
pared to isogenic p53 wild-type cells.
When these tumor cells were xenografted
in nude mice fed a diet lacking serine,
p53-deficient tumors exhibited a stronger
decrease in tumor volume than wild-
type tumors (Maddocks et al., 2013). It
has recently been shown that serine
deprivation forces cancer cells into a
‘‘fuel-efficient mode’’ where the glycolytic
intermediate 3-phosphoglycerate (3-PG)
shuttles into the Serine Synthesis Path-
way (SSP), while pyruvate enters the
TCA cycle, thereby increasing oxidative
phosphorylation and limiting the produc-
tion of lactate (Chaneton et al., 2012).
Maddocks et al. found that SSP enzymes
were similarly activated upon serine
starvation, independent of p53 status,
ruling out a defective SSP and subse-
quent improper de novo serine synthesis
as a potential candidate for the observed
proliferative failure in p53/ cells (Mad-
docks et al., 2013). Using oxygen
consumption as a read-out for oxidative, February 5, 2013 ª2013 Elsevier Inc. 159
Figure 1. Schematic of p53 Controlling Metabolic Fate upon Serine Starvation
Through glycolysis, glucose is converted into 3-PG (3-phosphoglycerate) and shuttled into the serine
synthesis pathway, as the demand for serine is great. Serine is then converted into glycine, where p53
is elevated and activates p21 to promote cell-cycle arrest and replenish GSH (glutathione). Conversion
to inosine monophosphate (IMP) and resultant purine biosynthesis is suppressed. GSH pools suppress
reactive oxygen species (ROS) generated from the TCA cycle. Cells lacking p53 or p21 generate IMP
instead of replenishing GMP pools and succumb to excessive ROS.
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Previewsphosphorylation, the authors showed that
serine deprivation increased oxygen
consumption in p53/ colon cancer cells
while p53+/+ cells had decreased respira-
tion. Although the glycolytic flux chan-
neled to the TCA cycle was initially
indistinguishable between the two geno-
types, TCA intermediates returned to
basal levels in wild-type cells, while p53-
deficient cells sustained cycling after
serine starvation, therefore increasing
oxygen consumption (Maddocks et al.,
2013). In the absence of serine, 3-PG
was rerouted toward serine synthesis,
which limited the amount of pyruvate
available for ATP production. The authors
then tested the hypothesis that increasing
TCA cycle flux by adding exogenous
pyruvate would restore ATP levels and
improve proliferation after serine starva-
tion: indeed, a partial rescue of cellular
proliferation was observed, caused
specifically by an increase in TCA flux
and not from the de novo conversion of
3-PG into serine.
Serine is converted through a glycine
intermediate to produce either inosine
monophosphate (IMP) to generate160 Cell Metabolism 17, February 5, 2013 ª2purines (GMP and AMP) or glutathione
(GSH), a known antioxidant (Figure 1).
Maddocks et al. found that serine starva-
tion decreased GMP and AMP levels in
both p53+/+ and p53/ colon cancer
cells (Maddocks et al., 2013). Depleted
GMP has been shown to induce a p53/
p21-dependent cell-cycle arrest (Linke
et al., 1996). Consistent with these find-
ings, serine starvation increased p53
expression levels, which markedly
induced p21 levels to trigger a transient
cell-cycle arrest, not observed in either
p53/ or p21/ isogenic cancer cells
(Maddocks et al., 2013). Moreover, cell
survival in p21/ cancer cells was
similar to isogenic p53/ cancer cells,
underscoring the importance of p21
activation after serine removal. Lastly,
the authors found that p53 expression
levels influenced serine utilization and
showed that p53+/+ cancer cells failed to
convert serine into IMP while both
p53/ and p21/ isogenic cancer cells
retained this ability. Conversely, although
GSH levels decreased after serine
starvation, p53+/+ cancer cells enhanced
GSH flux, unlike the p53/ or p21/013 Elsevier Inc.isogenic cells. To test the importance
of the antioxidant activity of GSH,
exogenous GSH was added to p53/
cells starved of serine. Cellular prolifera-
tion was only partially rescued with
the addition of GSH, while it was fully
restored when GSH was combined with
exogenous pyruvate (Maddocks et al.,
2013).
Taken together, this study reveals that
the proliferative defects seen in p53/
cells after serine starvation result from
decreased pyruvate caused by the
shuttling of glycolytic intermediates
into serine biosynthesis, as well as the
lack of GSH production to combat
increased ROS generated from the TCA
cycle. Furthermore, as serine starvation
decreases GMP levels, p53 is activated
and induces a p21 transient cell-cycle
arrest, allowing for a recovery in GSH
pools (Figure 1). The study by Maddocks
et al. raises a number of interesting
questions. How does p53 sense meta-
bolic distress under serine starvation or
other metabolic stimuli? Additionally,
since p21 is not critical for p53-mediated
tumor suppression (Li et al., 2012), are
additional downstream partners of
p53 regulating this pathway? Considering
the specific regulation of the M2 isoform
of pyruvate kinase (PKM2) in cancer,
as well as the suppression of PKM2
activity by serine deprivation (Chaneton
et al., 2012) and the described roles
for p53, it is tempting to speculate that
p53 may regulate PKM2 activity, or vice
versa.
The study by Maddocks et al. adds
to the complexity of the roles of p53 in
tumor suppression. Targeting metabolic
enzymes involved in the serine synthesis
pathway or in the production of gluta-
thione that can either mimic or work in
concert with serine starvation may help
in the design of future therapies for
cancers harboring mutated or complete
loss of p53.REFERENCES
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